Zhen Li, ADARx Pharmaceuticals CEO
A new player joins the RNA editing race on the heels of Eli Lilly's $1B-plus deal
A day after Eli Lilly inked a $1 billion-plus deal to partner with a quiet RNA editing startup, a new player has emerged to turn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
